ID
45508
Beskrivning
Principal Investigator: Ronald M. Krauss, MD, University of California San Francisco, Oakland, CA, USA MeSH: Hypercholesterolemia,Cardiovascular Diseases,Hydroxymethylglutaryl-CoA Reductase Inhibitors https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000481 The Cholesterol and Pharmacogenetics Study was a 6-week open label, non-randomized study of 40mg/day simvastatin treatment in 335 black and 609 white (944 total) men and women. Plasma lipids and lipoproteins were measured on two occasions prior to treatment and at 4 and 6 weeks of treatment. The study was designed to test for genetic associations with baseline measurements and changes in response to simvastatin treatment. Whole genome genotyping was performed on 592 white CAP study participants in two stages. In Stage 1, 304 were genotyped for 314,621 SNPs to tag for common genomic variation. In Stage 2, 290 participants were genotyped, including 280 who were genotyped for 620,901 SNPs. Two samples were excluded due to gender discrepancies. More recently, CAP self-reported black participants were genotyped on Illumina Omni2.5Exome chips. PolyA-selected strand-specific RNA-seq libraries were generated in several batches from lymphoblastoid cell lines (LCLs) derived from 268 white and 165 black CAP participants. The LCLs were exposed to sham buffer (control) or 2 uM activated simvastatin for 24 hours, producing a total of 866 100/101 bp paired end RNA-seq libraries sequenced on Illumina HiSeq 2000 machines.
Länk
Nyckelord
Versioner (2)
- 2022-11-16 2022-11-16 - Kristina Keller
- 2022-12-13 2022-12-13 - Kristina Keller
Rättsinnehavare
Ronald M. Krauss, MD, University of California San Francisco, Oakland, CA, USA
Uppladdad den
13 december 2022
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs000481 Cholesterol and Pharmacogenetics (CAP) Study
Subject ID and consent group of participants involved in the "Cholesterol and Pharmacogenetics (CAP) Study" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants involved in the "Cholesterol and Pharmacogenetics (CAP) Study" project.
- Subject ID, sample ID, and sample use variable obtained from participants involved in the "Cholesterol and Pharmacogenetics (CAP) Study" project.
- Subject ID, genotyping platform, gender, race, age, BMI, smoking status, mean triglyceride level in blood, mean total cholesterol in blood, mean low-density lipoprotein cholesterol level in blood, mean low-density lipoprotein cholesterol level in blood, mean high-density lipoprotein cholesterol level in blood, enrollment visit placebo pill count compliance (%), visit 1, 2 and 3 simvastatin pill count compliance (%) of Subject ID, sample ID, and sample use variable obtained from participants involved in the "Cholesterol and Pharmacogenetics (CAP) Study" project.
- pht003163.v3.p2
- Sample ID, body site where sample was collected, analyte type, tumor status, and histological type of samples of participants involved in the "Cholesterol and Pharmacogenetics (CAP) Study" project.
Similar models
Subject ID and consent group of participants involved in the "Cholesterol and Pharmacogenetics (CAP) Study" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants involved in the "Cholesterol and Pharmacogenetics (CAP) Study" project.
- Subject ID, sample ID, and sample use variable obtained from participants involved in the "Cholesterol and Pharmacogenetics (CAP) Study" project.
- Subject ID, genotyping platform, gender, race, age, BMI, smoking status, mean triglyceride level in blood, mean total cholesterol in blood, mean low-density lipoprotein cholesterol level in blood, mean low-density lipoprotein cholesterol level in blood, mean high-density lipoprotein cholesterol level in blood, enrollment visit placebo pill count compliance (%), visit 1, 2 and 3 simvastatin pill count compliance (%) of Subject ID, sample ID, and sample use variable obtained from participants involved in the "Cholesterol and Pharmacogenetics (CAP) Study" project.
- pht003163.v3.p2
- Sample ID, body site where sample was collected, analyte type, tumor status, and histological type of samples of participants involved in the "Cholesterol and Pharmacogenetics (CAP) Study" project.
Inga kommentarer